Sage Therapeutics, Inc.
SAGE
$7.97
$0.1051.34%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -83.56% | 337.08% | 249.80% | 139.89% | 2,621.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -83.56% | 337.08% | 249.80% | 139.89% | 2,621.54% |
| Cost of Revenue | -35.43% | -43.33% | -34.30% | -21.55% | -4.63% |
| Gross Profit | -477.26% | 54.42% | 41.71% | 27.47% | 91.54% |
| SG&A Expenses | -0.84% | -31.89% | -25.91% | -19.99% | -18.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.54% | -37.52% | -30.63% | -20.90% | -23.29% |
| Operating Income | -89.99% | 43.22% | 34.70% | 24.31% | 72.52% |
| Income Before Tax | -192.85% | 53.60% | 35.85% | 26.12% | 77.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -192.85% | 53.60% | 35.85% | 26.12% | 77.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -192.85% | 53.60% | 35.85% | 26.12% | 77.77% |
| EBIT | -89.99% | 43.22% | 34.70% | 24.31% | 72.52% |
| EBITDA | -91.53% | 43.26% | 34.76% | 24.37% | 72.74% |
| EPS Basic | -186.76% | 54.52% | 36.66% | 26.68% | 77.96% |
| Normalized Basic EPS | -119.88% | 45.42% | 36.66% | 26.68% | 77.81% |
| EPS Diluted | -186.76% | 54.52% | 36.66% | 26.68% | 77.96% |
| Normalized Diluted EPS | -119.88% | 45.42% | 36.66% | 26.68% | 77.81% |
| Average Basic Shares Outstanding | 2.12% | 2.01% | 1.29% | 0.77% | 0.83% |
| Average Diluted Shares Outstanding | 2.12% | 2.01% | 1.29% | 0.77% | 0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
